Mr Christopher Belder
School of Medicine
College of Health
| Date | Institution name | Country | Title |
|---|---|---|---|
| The University of Adelaide | Australia | Bachelor of Medicine, Bachelor of Surgery (MBBS) |
| Date | Title | Institution | Country |
|---|---|---|---|
| Fellow of the Royal Australasian College of Physicians (FRACP) | Royal Australasian College of Physicians | Australia |
| Year | Citation |
|---|---|
| 2026 | Belder, C. R. S., Heslegrave, A. J., Swann, O., Abel, E., Beament, M., Nasir, M., . . . Fox, N. C. (2026). Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.. medRxiv. |
| 2026 | Belder, C. R. S., & Fox, N. C. (2026). Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer’s disease. Journal of Neurology Neurosurgery and Psychiatry, 97(7), 568. |
| 2026 | Llorente-Saguer, I., Gabriele, R., Bradshaw, T. Y., Leckey, C. A., Belder, C. R. S., Chávez-Gutiérrez, L., . . . Arber, C. (2026). Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer’s disease. Brain Communications, 8(2), fcag105. |
| 2026 | Tonietto, M., Silvestri, E., Belder, C. R. S., Barkhof, F., Fox, N. C., Smith, J., & Klein, G. (2026). Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. Alzheimer S and Dementia, 22(8), e71749. |
| 2026 | Belder, C. R. S., Heslegrave, A. J., Swann, O., Abel, E., Beament, M., Nasir, M., . . . Fox, N. C. (2026). Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing. Journal of Neurology, Neurosurgery and Psychiatry, 1-10. |
| 2025 | O'Connor, A., Ryan, N. S., Belder, C. R. S., Lynch, D. S., Lahiri, N., Houlden, H., . . . O'Dowd, S. (2025). Genetic testing in dementia. Practical Neurology, 25(2), 127-136. Scopus3 WoS2 Europe PMC2 |
| 2025 | Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., . . . Fox, N. C. (2025). Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority – Authors' reply. The Lancet Neurology, 24(3), 190. Scopus2 Europe PMC1 |
| 2025 | Rosa-Grilo, M., Chughtai, H. R., Thomas, D. L., Alexander, D. C., Beament, M., Belder, C. R. S., . . . Fox, N. C. (2025). Ultra-fast MRI for dementia diagnosis and treatment eligibility: A prospective study. Alzheimer S and Dementia, 21(6), 12 pages. Scopus3 WoS3 Europe PMC2 |
| 2025 | Wisch, J. K., McKay, N. S., Zammit, M., Christian, B. T., Schultz, S. A., Millar, P. R., . . . Gordon, B. (2025). Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease. Alzheimer S and Dementia, 21(10), 11 pages. Scopus1 WoS1 Europe PMC2 |
| 2025 | Fox, N. C., Belder, C., Ballard, C., Kales, H. C., Mummery, C., Caramelli, P., . . . Frisoni, G. B. (2025). <i>The</i><i> Lancet</i> Series on Alzheimer's Disease 2 Treatment for Alzheimer's disease. LANCET, 406(10510), 1408-1423. WoS74 Europe PMC40 |
| 2025 | Parker, C. S., Veale, T., Malone, I. B., Belder, C., O'Connor, A., Abel, E., . . . Weston, P. S. J. (2025). Longitudinal trajectories of advanced cortical diffusion‐weighted imaging measures of tissue microstructure in pre‐symptomatic autosomal dominant Alzheimer’s disease. Alzheimer's & Dementia, 21(S7). |
| 2024 | Belder, C. R. S., Marshall, C. R., Jiang, J., Mazzeo, S., Chokesuwattanaskul, A., Rohrer, J. D., . . . Warren, J. D. (2024). Primary progressive aphasia: six questions in search of an answer. Journal of Neurology, 271(2), 1028-1046. Scopus43 WoS37 Europe PMC34 |
| 2024 | Arber, C., Belder, C. R. S., Tomczuk, F., Gabriele, R., Buhidma, Y., Farrell, C., . . . Wray, S. (2024). The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations. Alzheimer's and Dementia, 20(7), 4717-4726. Scopus8 WoS8 Europe PMC12 |
| 2024 | Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., . . . Fox, N. C. (2024). Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy. Lancet Neurology, 23(10), 1025-1034. Scopus65 WoS65 Europe PMC58 |
| 2023 | Belder, C. R. S., Chokesuwattanaskul, A., Marshall, C. R., Hardy, C. J. D., Rohrer, J. D., & Warren, J. D. (2023). The problematic syndrome of right temporal lobe atrophy: Unweaving the phenotypic rainbow. Frontiers in Neurology, 13, 1082828-1-1082828-6. Scopus18 WoS17 Europe PMC19 |
| 2023 | Belder, C. R. S., Schott, J. M., & Fox, N. C. (2023). Preparing for disease-modifying therapies in Alzheimer's disease. Lancet Neurology, 22(9), 782-783. WoS69 Europe PMC64 |
| Year | Citation |
|---|---|
| 2024 | Llorente-Saguer, I., Gabriele, R., Bradshaw, T., Leckey, C. A., Belder, C. R. S., Chávez-Gutiérrez, L., . . . Arber, C. (2024). Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer’s disease. DOI |
| 2023 | Arber, C., Belder, C. R. S., Tomczuk, F., Gabriele, R., Buhidma, Y., O’Connor, A., . . . Wray, S. (2023). The presenilin 1 mutation P436S causes familial Alzheimer’s disease with elevated Aβ43 and atypical clinical manifestations. DOI |
Connect With Me
External Profiles
